I n addition to its classical role as an endocrine system, evidence suggests that all components of the renin-angiotensin system (RAS) exist in individual tissues, [1] [2] [3] resulting in the local synthesis, release, and action of angiotensin II (Ang II). The brain RAS 4 -6 is hypothesized to contribute to normal regulation of blood pressure (BP) and volume homeostasis through its effects on sympathetic outflow 7 and vasopressin synthesis and release. 8, 9 Ang II type 1 (AT 1 ) receptors are densely localized in several regions of the central nervous system (CNS) involved in cardiovascular regulation, including structures of the lamina terminalis of the forebrain, 10 -12 brain stem sites such as the nucleus of the solitary tract, ventrolateral medulla, 6, 13, 14 and hypothalamic paraventricular and supraoptic nuclei. 12 Several AT 1 -rich sites lack a blood-brain-barrier, eg, subfornical organ, organum vasculosum of the lamina terminalis, area postrema, and median preoptic nucleus, thus allowing direct interfacing with circulating Ang II. Brain AT 1 receptor activation by both locally and systemically derived Ang II is thought to modulate normal processing of sensory input and neurohumoral outflow. 15, 16 Moreover, studies showing increased density or activity of AT 1 receptors in these cardiovascular control regions in various genetic and experimental hypertension models have implicated central AT 1 receptors as causal in the development and maintenance of hypertension. [17] [18] [19] Classical physiological and pharmacological approaches have demonstrated the importance of the brain RAS in regulating cardiovascular homeostasis. Recently developed transgenic strategies now permit further dissection of the precise mechanisms by which this occurs. Using gene targeting, we recently examined the relative contribution of AT 1 receptor subtypes, AT 1a and AT 1b , to central Ang II responses. 20 Although these studies did clarify that Ang II-elicited BP increase can be selectively ascribed to the AT 1a subtype, whereas AT 1b receptors are necessary for the drinking response, they did not allow us to definitively establish the relative roles of central versus peripheral AT 1 receptors because the genes were deleted globally.
The specific objective of this study was to develop a novel transgenic model with CNS-targeted AT 1 receptors, with the overall goal of unraveling the relative contribution of brain versus peripheral vascular and extravascular AT 1 receptors to BP regulation. We chose to overexpress the AT 1a receptor based on our earlier findings that this subtype, but not AT 1b , is critical in mediating central Ang II BP responses.
Materials and Methods

Generation of Transgenic Mice and Animal Husbandry
A fusion transgene (NSE-AT 1a ) consisting of 4 kb of the rat neuron-specific enolase (NSE) 5Ј flanking region (kind gift of J.G. Sutcliffe, Scripps Research Institute, La Jolla, Calif) [21] [22] [23] and a cDNA encoding the full open-reading frame of the rat AT 1a receptor (kind gift of K.E. Bernstein, Emory University, Atlanta, Ga) 24 was constructed ( Figure 1A ). The transgene segment was obtained by digestion with SalI, separated by agarose gel electrophoresis, and recovered using the Qia-Quick gel purification kit (Qiagen). Transgenic mice were generated by microinjection into fertilized C57BL/ 6JXϫSJL/J (B6SJL F2) mouse embryos, and positive founders (see next paragraph) were bred for study as described previously. 25 All mice were fed standard mouse chow (LM-485; Teklad Premier Laboratory Diets) and water ad libitum. Care of the mice used in the experiments exceeded the standards set forth by the NIH in their guidelines for the care and use of experimental animals. All procedures were approved by the University Animal Care and Use Committee at the University of Iowa.
Analysis of Nucleic Acids
Genomic DNA was purified from tail biopsies and subjected to either Southern blot analysis for identification of positive founders ( Figure  1A ) or to PCR for identification of transgenic offspring, both described in detail previously. 26, 27 Transgene expression was analyzed using RNase protection assay (RPA) and a cDNA probe derived from a region of rat AT 1a sequence with relatively lower nucleotide homology to the mouse sequence compared with the rest of the gene (184 -586 relative to transcription start site). The probe was PCR-amplified from rat genomic DNA, cloned into pCRII (Invitrogen), and single-stranded antisense RNA was generated by an in vitro transcription reaction containing T7 polymerase and ␣-32 P[UTP]. To obtain sufficient RNA from peripheral neural tissues, ganglia and nerve bundles were widely harvested and combined from cervical, para-aortic, and extremity sites. RPAs were performed using the HybSpeed RPA kit (Ambion) following the manufacturer's instructions and as described previously. 27 Quantification was performed using a PhosphorImager SI system (Molecular Dynamics) in conjunction with ImageQuant software (version 5.0). AT 1a mRNA levels were normalized by dividing the AT 1a signal by the mouse ␤-actin signal.
Detection of AT 1 Receptor Protein
Analysis of AT 1 receptor levels in brain of transgenic and nontransgenic mice was performed by Western blot analysis as described previously 28 using a rabbit polyclonal antibody (Santa Cruz, sc-579, 1:100 dilution). Intensities of the bands were analyzed by densitometry using ImageQuant software (see previous paragraph).
Immunofluorescent localization of AT 1 receptor protein in brain of transgenic mice (6084-2 nϭ5; 6085-2 nϭ5) and nontransgenic controls (nϭ5) was performed using a rabbit polyclonal antibody targeted against the carboxyl terminus of the rat AT 1a receptor (kindly provided by Dr M. McKinley, Howard Florey Institute, Parkville, Victoria, Australia). As described in detail previously, 29 brains were perfused, postfixed overnight, and cryosectioned (30 m, coronal). Free-floating sections were subjected to immunofluorescence staining using the tyramide signal amplification method as described previously 30 and incubated with AT 1 receptor antibody for 48 hours (1:5000 dilution). In addition to specificity controls, a dilution series for AT 1 antibody was carried out (1:5000, 1:10 000, 1:20 000), and comparable AT 1 immunofluorescence was observed at all concentrations. Finally, primary antibody was omitted in some incubations (transgenic and control) to check for autofluorescence. Confocal microscopy (Zeiss LSM 510) was used to analyze immunohistochemical staining (488 nm for visualization of fluorescein). Anatomical analyses were performed with the aid of a mouse brain atlas. 31 
Physiological Studies
NSE-AT 1a transgenics from two different founder lines (6085-2, nϭ9; 6084-2, nϭ7) and nontransgenic controls (nϭ12) were surgically instrumented with intracerebroventricular (ICV) and left common carotid arterial cannulae for central administration of drugs and measurement of cardiovascular parameters, respectively, as described previously. 27 In the first set of experiments, the dosedependent effects of Ang II (50 to 200 ng; 200 nL) were determined. Doses were given randomly, only two consecutive injections were performed in each mouse, and at least 30 minutes was allowed between injections. Baroreflex sensitivity was estimated using linear regression analysis for the central Ang II-induced cardiovascular changes in heart rate and mean arterial pressure (⌬HR/⌬MAP) as described previously. 27, 32 To confirm AT 1 receptor involvement, mice (6084-2, nϭ5; 6085-2, nϭ5; nontransgenics, nϭ5) were pretreated ICV with either saline or the AT 1 receptor antagonist losartan (20 g) followed 20 minutes later by ICV injection of the highest dose of Ang II (200 ng). Finally, to determine the selectivity of the cardiovascular responses to Ang II, we also examined the effects of another central pressor agent, the cholinergic agonist carbachol (50 ng ICV), in a separate group of transgenic (6085-2, nϭ4; 6084-2, nϭ4) and nontransgenic (nϭ4) mice.
Statistics
Data are expressed as meanϮSEM. Data were analyzed by Student's t test or ANOVA (following Bartlett's test of homogeneity of variance) followed by Newman-Keuls correction for multiple comparisons. Statistical analyses were performed using Prism (version 3.0) software package (GraphPad Software Inc).
Results
Six NSE-AT 1a transgenic founders (of 59 pups born) containing varying copies of the transgene were identified by the presence of a 4.4-kb hybridization band on Southern blots ( Figure 1B ). All six founders were successfully bred to establish transgenic lines, with transmission of the transgene to Ϸ50% of male and female offspring. By using RPA, three separate transgenic lines with differing levels of transgene mRNA in brain were identified (6084-2, 6055-1, and 6085-2) (Figures 2A and 2B ). Line 6084-2 exhibited the highest level of transgene expression, while lines 6085-2 and 6055-1 exhibited more moderate levels.
Focusing on these 3 lines, we next determined whether the transgene was indeed expressed selectively in brain. Total RNA was purified from a wide variety of tissues of both male and female transgenic and nontransgenic mice and was subjected to RPA using the same transgene-specific probe. A representative RPA of a positive NSE-AT 1a (line 6085-2) mouse and a nontransgenic littermate is shown in Figures 2C  and 2D . High-level expression of the transgene was detected in brain but in no other tissues examined in line 6085-2, and the lack of expression in brain or any other tissues in nontransgenic controls further confirmed selectivity of the probe. Extremely low-level expression of rat AT 1a receptors was detected in the adrenal gland of 6085-2 mice, but interestingly, the transgene was undetectable in peripheral neural tissue. This observation was confirmed using RT-PCR (data not shown). The same brain-restricted (and very lowlevel adrenal) expression pattern was observed in line 6084-2, and no sex-related differences in expression level or pattern were observed in either line. In contrast, line 6055-1 exhibited widespread expression of the transgene with varying levels between males and females, thus further studies were restricted to lines 6084-2 and 6085-2.
To determine whether NSE-AT 1a transgene expression was also reflected at the protein level, Western blot analysis was performed on brains from 6084-2 and 6085-2 mice and nontransgenic littermates. Because all available antibodies cross-react with both mouse and rat AT 1 receptors, we compared brain AT 1 protein levels in transgenic mice with baseline levels of the protein in nontransgenic controls. As shown in Figure 3 , both 6084-2 and 6085-2 mice exhibit enhanced AT 1 receptor protein (Ϸ70-kDa band) in brain compared with nontransgenic animals, and the relative levels are correlated to mRNA levels for these two lines (see Figure 2) .
Distribution of transgene expression in brain of 6084-2 and 6085-2 mice was determined using immunohistochemistry and confocal microscopy. The AT 1 receptor antibody used for these studies was specifically developed for use in brain immunocytochemistry at light and electron microscopic levels. 33 Although the antibody does not distinguish between 
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Brain-Selective AT 1a Receptor Overexpressionendogenous and transgenic (rat) AT 1 receptors, a comparison of distribution and fluorescence intensity between transgenic and nontransgenic mice allowed us to qualitatively estimate relative levels of transgene expression. Widespread AT 1 receptor immunofluorescence was detected throughout the brain of both transgenic lines, with a similar distribution pattern in each line (see online data supplement available at http://www.circresaha.org). This is in contrast to the rather discrete localization of AT 1 receptors to a few areas of the brain, most notably components of the lamina terminalis of the forebrain, brain stem nuclei such as the nucleus of the solitary tract, ventrolateral medulla, and hypothalamic areas, in nontransgenic mice and in rats using this antibody. 33 In addition to a more widespread distribution, abundance of AT 1 receptors was markedly elevated in both transgenic lines compared with controls and generally higher in 6084-2 versus 6085-2 mice. This is illustrated in typical confocal images ( Figures 4A through 4F ) of two representative regions, the lateral hypothalamic area (left panels) and the supraoptic nucleus (right panels), where AT 1 receptor staining is highly abundant in 6084-2 ( Figures 4A and 4B ), abundant in 6085-2 ( Figures 4C and 4D ) and either undetectable or at low levels in nontransgenic ( Figures 4E and 4F ) mice. Figures 4G and  4H ) demonstrates low levels of background staining in sections from nontransgenics, indicating that AT 1 immunostaining observed in transgenic animals is not due to nonspecific activity of the antibody. A complete lack of immunofluorescence in sections (transgenic and controls; data not shown) incubated without the primary antibody further confirms the specificity of staining. Strict neuron-specific localization of the transgene in brain of NSE-AT 1a mice is difficult to demonstrate because of the cross-reactivity of the AT 1 antibody with both the transgene and endogenous AT 1 receptors that may be localized to glial cells. 34 -36 However, we performed morphological analyses to confirm localization of AT 1 immunostaining in neurons. As seen in representative examples in Figures 4A, 4C , and 4E), AT 1 staining was observed in cell bodies and fibers with morphological characteristics typical of neurons. This neuronal pattern of staining was observed throughout the brain in both transgenic lines.
To demonstrate functional expression of exogenous AT 1a receptors in NSE-AT 1a transgenic mice, we examined the dose-dependent effects of central acute administration of Ang II on MAP and HR in conscious freely moving mice. Resting MAP and HR values before Ang II are summarized (see Table) . The only significant alteration in basal cardiovascular values was a significant tachycardia observed in 6084-2 mice. There were no significant differences in baseline MAP between either transgenic line and nontransgenic littermates, indicating that brain-selective overexpression of AT 1a receptors did not cause hypertension under conditions of basal RAS activation. However, both transgenic lines exhibited significantly enhanced cardiovascular sensitivity to central Ang II compared with controls ( Figure 5 ). In nontransgenics, Ang II caused typical pressor and bradycardic responses observed previously in mice 21 and in many other species, 6, 32, 37 but the magnitude of these responses was dramatically increased in both transgenic lines ( Figure 6 ). This is in contrast to the equivalent cardiovascular effects (PϾ0.05 for all comparisons) produced by the central pressor agent, carbachol, 38 in nontransgenic (⌬MAP, 14Ϯ1 mm Hg; ⌬HR, Ϫ61Ϯ11 bpm, nϭ4), 6084-2 (⌬MAP, 17Ϯ3 mm Hg; ⌬HR, Ϫ74Ϯ21 bpm), and 6085-2 (⌬MAP, 13Ϯ1 mm Hg; ⌬HR, Ϫ73Ϯ27 bpm, nϭ4) mice. In addition, central Ang II-induced baroreflex responses were significantly enhanced in both 6085-2 and 6084-2 (Ϫ3.62Ϯ0.46 and Ϫ6.3Ϯ0.47 bpm/mm Hg, respectively; PϽ0.05) compared with nontransgenics (Ϫ1.98Ϯ0.28 bpm/mm Hg). To confirm that the enhanced cardiovascular sensitivity to central Ang II in NSE-AT 1a transgenics is indeed due to AT 1 receptors and not some other mechanism, we examined the effects of losartan on Ang II-induced cardiovascular responses in separate animals ( Figure 6B ). Interestingly, losartan itself caused a significant decrease in baseline MAP in both transgenic lines (6085-2: ⌬MAP Ϫ18Ϯ2 mm Hg; 6084-2: ⌬MAP Ϫ11Ϯ2 mm Hg; PϽ0.01 versus control) but had no effect on MAP in nontransgenic mice (1Ϯ2 mm Hg). The Ang IIinduced pressor and bradycardic responses were completely abolished by pretreatment with the AT 1 antagonist in both transgenic lines and in controls, confirming that AT 1 receptors are essential in mediating the Ang II-induced cardiovascular effects in all three groups.
In addition to markedly different effects of central Ang II on the magnitude of MAP and HR responses in NSE-AT 1a and control mice, the time course of these cardiovascular changes differed between the groups. In control mice, the increase in BP and decrease in HR were similar in duration (4.42Ϯ0.27 and 6.43Ϯ1.2 minutes, respectively), indicative of activation of baroreflex mechanisms. In contrast, both transgenic lines exhibited much longer-lasting bradycardic responses relative to the duration of the pressor responses. Whereas the Ang II-induced increases in BP were of significantly longer duration in both transgenic lines compared with controls (6085-2: 7.47Ϯ0.39 minutes; 6084-2: 6.73Ϯ0.88 minutes; PϽ0.05), the bradycardic response persisted long after the BP had returned to baseline in these mice 
Discussion
Intrinsic tissue RAS, defined as tissue-based systems with the potential for local Ang II production and activity, have been hypothesized to play critical roles in cardiovascular regulation that are distinct from that mediated by the classical systemic RAS. However, the importance of this mechanism remains unresolved because of the difficulty in experimentally dissecting tissue and systemic RASs. The brain RAS is particularly controversial in this regard because of the direct interfacing of central Ang II receptors with circulating Ang II at brain regions lacking a blood-brain-barrier. As an initial step toward dissecting the relative physiological significance of brain versus peripheral vascular and extravascular Ang II receptors, we report herein the development of a novel transgenic mouse model with functional expression of exogenous AT 1a receptors selectively in the brain. Our long-term goal is to utilize these mice to examine the physiological consequences of overexpression of AT 1a receptors selectively in brain of normal mice (with intact endogenous AT 1 receptors) and in mice otherwise devoid of AT 1a receptors through breeding onto the AT 1a -null background. 27, 39 Of six transgenic founders harboring the rat AT 1a receptor under the control of the NSE promoter, two individually derived lines exhibited exogenous AT 1a mRNA almost exclusively in the brain. No other tissues were positive for rat AT 1a mRNA except low-level expression in the adrenal gland, which was not surprising given that medullary chromaffin 40 We chose the NSE promoter because NSE is a distinct isoform of the glycolytic enzyme enolase found only in terminally differentiated neurons and neuroendocrine cells, whereas a different enolase isozyme (non-neuronal enolase) is expressed in neuroblasts and all other non-neuronal cells of the CNS. 40 Hence, NSE-driven transgenes are reported to be neuron-selective. 21 ,22,41 Although we could not rule out the possibility of AT 1a transgene expression in astrocytes or other non-neuronal cells, our morphological analyses suggest significantly enhanced AT 1 receptor staining in neurons of NSE-AT 1a mice. Consistent with the finding that NSE is one of the most abundantly expressed and widely distributed proteins in the adult mammalian brain, 42 NSE-AT 1a transgenics exhibited AT 1a immunostaining at high levels throughout most brain regions. The losartan-sensitive enhanced cardiovascular responsiveness of both transgenic lines to acute central Ang II is presumably the functional consequence of overexpression of AT 1a receptors observed in cardiovascular control regions of these mice. These data provide important evidence for functional expression of the transgene. Interestingly, the AT 1a expression level is not directly correlated with cardiovascular sensitivity in the two transgenic lines. This may be interesting with regard to differential regulation and/or neural circuitry associated with transgene expression in these two different transgenic lines. The mechanism of enhanced cardiovascular sensitivity to central Ang II in NSE-AT 1a mice is the subject of ongoing investigations.
Overexpression of AT 1a receptors in brain stem sites known to regulate sympathetic outflow 43 and in hypothalamic nuclei involved in vasopressin synthesis and release 44, 45 raises the possibility that one or both of these mechanisms is involved in the hyperresponsiveness of NSE-AT 1a mice. The relative effect of systemically versus centrally administered Ang II in the context of AT 1a overexpression observed in circumventricular organs of these mice is also of considerable ongoing interest.
Interestingly, despite increased Ang II-elicited pressor and bradycardic responses, NSE-AT 1a transgenics are not hypertensive at rest. At first, this may seem to contradict earlier held notions that increased levels of AT 1 receptor protein, mRNA, or binding activity found in central cardiovascular control regions of various genetic and experimental models of hypertension were responsible for the increased BP in these models. 17, 18 However, the present data and earlier findings can be reconciled by postulating that increased brain AT 1 receptor levels alone do not cause centrally mediated hypertension, but activation of the RAS, ie, increased production of Ang II, either centrally or peripherally, is also required. We are currently investigating this possibility by examining the effects of sustained RAS activation on baseline BP in NSE-AT 1a mice using radiotelemetry.
Another explanation for normal resting BP in mice with functional overexpression of brain AT 1a receptors is that baroreflex activity is particularly effective in maintaining BP homeostasis in the face of increased receptor numbers. This is supported by our finding that NSE-AT 1a mice exhibit significant depressor responses to ICV losartan, whereas central blockade of AT 1 receptors has no effect on baseline BP in control mice. Furthermore, centrally induced baroreflex responses seem enhanced in both transgenic lines compared with controls as suggested by our baroreflex estimation. Taken together, these results suggest that although there is an enhanced contribution of central AT 1 receptors to the maintenance of baseline BP in NSE-AT 1a transgenic mice, effective baroreflex buffering prevents hypertension in this model. However, a complete understanding of baroreflex function in this model will require direct investigation of HR changes elicited over a range of centrally and peripherally induced changes in BP. 32 Analysis of baroreflex function in NSE-AT 1a transgenics is also of interest given the persistent bradycardia observed in these mice long after return of BP to baseline on ICV Ang II. Indeed, the temporal profile of this response suggests that at least a portion of the Ang II-induced bradycardia is not directly the result of baroreflex activity. One possible mechanism may involve the well-known sympathoinhibitory effects of vasopressin via actions at the area postrema. 46 It is plausible that overexpression of AT 1a receptors in NSE-AT 1a mice leads to enhanced Ang II-induced release of vasopressin, which in turn acts on area postrema neurons that interact with other hindbrain sites known to mediate sympathoinhibition. Alternatively, the long-lasting Ang II-elicited bradycardia may involve direct activation of areas involved in HR control, eg, the nucleus ambiguus, ventrolateral medulla, and nucleus tractus solitarius. Indeed, these areas exhibit highlevel overexpression of AT 1 receptors in the NSE-AT 1a transgenic mice.
The functional consequences of ectopic and noncardiovascular region-localized expression of AT 1a receptors in brain of NSE-AT 1a transgenic mice remain to be determined. Central AT 1 receptors have been implicated in a wide variety of responses that are apparently independent of BP regulation, including anxiety, 47 exploratory behavior, 48 dopamine formation and release, 49 and development, plasticity, and maturation of the brain. 50 This, coupled with the widespread distribution of AT 1 receptors in brain of NSE-AT 1a transgenics, makes these mice potentially useful models for exploring other noncardiovascular-related functions of AT 1 receptors.
In summary, we have developed a useful transgenic model that exhibits functional overexpression of AT 1a receptors selectively in the brain. Used both independently, and in conjunction with mice harboring gene-targeted deletions of AT 1a receptors, this new model will permit quantitative and relevant investigations of the role of central AT 1a receptors in cardiovascular homeostasis in health and disease.
